Multiple Sclerosis International / 2011 / Article / Tab 3 / Research Article
The Impact of Comorbid Depression on Adherence to Therapy for Multiple Sclerosis Table 3 Patient characteristics: MS patients treated with antidepressants for at least 6 months compared to MS patients treated with antidepressants for less than 6 months.
Characteristic
Treated less than guidelines (
)
Treated according to guidelines (
)
statistic
value
%
% Characteristics matched on Age N/A N/A <35 5 7.04 5 7.04 35–44 17 23.94 17 23.94 45–54 32 45.07 32 45.07 55–64 17 23.94 17 23.94 65+ 0 0 0 0 Sex N/A N/A Male 1 1.41 1 1.41 Female 70 98.59 70 98.59 Region N/A N/A Northeast 5 7.04 5 7.04 North Central 21 29.58 21 29.58 South 30 42.25 30 42.25 West 15 21.13 15 21.13 Unknown 0 0 0 0 Year of index date N/A N/A 2004 6 8.45 6 8.45 2005 17 23.94 17 23.94 2006 15 21.13 15 21.13 2007 28 39.44 28 39.44 2008 5 7.04 5 7.04 ITT DMT N/A N/A Avonex 11 15.49 11 15.49 Betaseron 3 4.23 3 4.23 Copaxone 44 61.97 44 61.97 Rebif 13 18.31 13 18.31 Tysabri 0 9 0 9 Other characteristics Insurance status Comprehensive 6 8.45 6 8.45 N/A N/A Health maintenance org 16 22.54 10 14.08 1.70 0.193 Point-of-service 10 14.08 6 8.45 1.13 0.288 Preferred provider org 39 54.93 45 63.38 1.05 0.306 Other 0 0 4 5.63 4.12 0.043 Copayment with ITT drug 61 85.92 54 76.06 2.24 0.134 Mail order for ITT drug 23 32.39 22 30.99 0.03 0.857 Preperiod Charlson score 0 45 63.38 40 56.34 0.73 0.392 1-2 20 28.17 26 36.62 1.16 0.282 3+ 6 8.45 5 7.04 0.09 0.754 Preperiod disability proxies Muscoloskeletal 46 64.79 48 67.61 0.13 0.723 Medical 35 49.30 42 59.15 1.39 0.238